0.337
0.00 (0.48%)
Previous Close | 0.336 |
Open | 0.335 |
Volume | 1,732,434 |
Avg. Volume (3M) | 2,292,619 |
Market Cap | 91,868,448 |
Price / Sales | 9.38 |
Price / Book | 7.09 |
52 Weeks Range | |
Earnings Date | 8 Aug 2024 - 12 Aug 2024 |
Operating Margin (TTM) | -808.43% |
Diluted EPS (TTM) | -0.310 |
Quarterly Revenue Growth (YOY) | 104.20% |
Current Ratio (MRQ) | 0.490 |
Return on Assets (TTM) | -76.18% |
Return on Equity (TTM) | -334.02% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Bearish | Mixed |
Medical Devices (Global) | Bearish | Mixed | |
Stock | Asensus Surgical, Inc. | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | 0.0 |
Average | -1.63 |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina. |
|
Sector | Healthcare |
Industry | Medical Devices |
% Held by Insiders | 2.06% |
% Held by Institutions | 18.27% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |